Nkarta マネジメント

マネジメント基準チェック /34

Nkartaの CEO はPaul Hastingsで、 Feb2018年に任命され、の在任期間は 6.75年です。の年間総報酬は$ 2.93Mで、 21.2%給与と78.8%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.11%を直接所有しており、その価値は$ 187.81K 。経営陣と取締役会の平均在任期間はそれぞれ4.1年と4.8年です。

主要情報

Paul Hastings

最高経営責任者

US$2.9m

報酬総額

CEO給与比率	21.2%
CEO在任期間	6.8yrs
CEOの所有権	0.1%
経営陣の平均在職期間	4.1yrs
取締役会の平均在任期間	4.8yrs

経営陣の近況

Recent updates

Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation

Nov 20

Nkarta GAAP EPS of -$0.61

Aug 11

We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate

Jun 09

Nkarta: A Promising Natural Killer Cell Play

May 20

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Aug 23

Nkarta (NASDAQ:NKTX) Is In A Good Position To Deliver On Growth Plans

May 10

Nkarta gets greenlight from the FDA for NKX019 cancer study

Apr 28

We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate

Jan 25

CEO報酬分析

Nkarta の収益と比較して、Paul Hastings の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$111m
Jun 30 2024	n/a	n/a	-US$108m
Mar 31 2024	n/a	n/a	-US$116m
Dec 31 2023	US$3m	US$624k	-US$118m
Sep 30 2023	n/a	n/a	-US$122m
Jun 30 2023	n/a	n/a	-US$125m
Mar 31 2023	n/a	n/a	-US$119m
Dec 31 2022	US$5m	US$600k	-US$114m
Sep 30 2022	n/a	n/a	-US$104m
Jun 30 2022	n/a	n/a	-US$98m
Mar 31 2022	n/a	n/a	-US$93m
Dec 31 2021	US$7m	US$576k	-US$86m
Sep 30 2021	n/a	n/a	-US$81m
Jun 30 2021	n/a	n/a	-US$72m
Mar 31 2021	n/a	n/a	-US$102m
Dec 31 2020	US$3m	US$560k	-US$91m
Sep 30 2020	n/a	n/a	-US$84m
Jun 30 2020	n/a	n/a	-US$73m
Mar 31 2020	n/a	n/a	-US$27m
Dec 31 2019	US$3m	US$543k	-US$21m

報酬と市場: Paulの総報酬 ($USD 2.93M ) は、 US市場 ($USD 1.48M ) の同規模の企業の平均を上回っています。

報酬と収益: Paulの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Paul Hastings (64 yo)

6.8yrs

在職期間

US$2,934,715

報酬

Mr. Paul J. Hastings had been President of Nkarta, Inc. since February 2018 until July 2024 and serves as its Chief Executive Officer as well as Director since February 2018. He is Independent Director of...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Paul Hastings	CEO & Director	6.8yrs	US$2.93m	0.11% $ 187.8k
Alyssa Levin	Chief Financial & Business Officer and Principal Accounting Officer	1.3yrs	US$1.51m	0% $ 0
David Shook	Chief Medical Officer & Head of Research and Development	1.8yrs	US$1.51m	0.029% $ 49.5k
Nadir Mahmood	President	less than a year	US$1.82m	0.044% $ 76.9k
Ralph Brandenberger	Chief Technical Officer	4.8yrs	データなし	0.0058% $ 10.0k
Greg Mann	Vice President of Public Affairs and Investor Relations	4.8yrs	データなし	データなし
Alicia Hager	Chief Legal Officer & Corporate Secretary	4.1yrs	US$2.06m	0.013% $ 22.8k

4.1yrs

平均在職期間

50yo

平均年齢

経験豊富な経営陣: NKTXの経営陣は経験豊富であると考えられます ( 4.1年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Paul Hastings	CEO & Director	6.8yrs	US$2.93m	0.11% $ 187.8k
Ali Behbahani	Independent Chairman	9.1yrs	US$166.75k	0% $ 0
Leone Patterson	Independent Director	4.6yrs	US$136.25k	0% $ 0
Lewis Lanier	Member of Scientific Advisory Board	no data	データなし	データなし
Michael Dybbs	Independent Director	5.3yrs	US$135.25k	0% $ 0
Simeon George	Independent Director	4.8yrs	US$126.25k	0% $ 0
Dario Campana	Member of Scientific Advisory Board	no data	データなし	データなし
Zachary Scheiner	Independent Director	4.8yrs	US$125.25k	0% $ 0
Angela Thedinga	Independent Director	2.7yrs	US$122.50k	0% $ 0
George Vratsanos	Director	less than a year	データなし	データなし

4.8yrs

平均在職期間

48yo

平均年齢

経験豊富なボード: NKTXの取締役会は経験豊富であると考えられます ( 4.8年の平均在任期間)。

Nkarta マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Nkarta, Inc. Announces Executive Appointments

Nkarta, Inc. Appoints George Vratsanos as Board of Directors

Nkarta, Inc., Annual General Meeting, Jun 13, 2024

CEO, President & Director notifies of intention to sell stock

CEO, President & Director recently sold US$85k worth of stock

Nkarta, Inc. Appoints Alyssa Levin as Chief Financial Officer

Recent updates

Price target decreased by 8.7% to US$15.83

Nkarta: Catalysts Ahead, But Competition In Cell Therapy Too (Rating Downgrade)

Price target decreased by 10% to US$17.33

We're Hopeful That Nkarta (NASDAQ:NKTX) Will Use Its Cash Wisely

Nkarta: NK Cell Therapy Biotech With Good Standing Targeting R/R NHL Patients

Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus

Nkarta, Inc. Announces Executive Appointments

Nkarta, Inc. Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications

Nkarta, Inc. Appoints George Vratsanos as Board of Directors

Nkarta: A Look Into Q1 Results And Upcoming Catalysts

Nkarta, Inc., Annual General Meeting, Jun 13, 2024

Nkarta: Down 50% Since March With A Clinical Catalyst Ahead

Nkarta, Inc. has completed a Follow-on Equity Offering in the amount of $240.10001 million.

New minor risk - Shareholder dilution

Nkarta: NK Cell Therapy Advancement On Two Fronts

Nkarta, Inc. has filed a Follow-on Equity Offering in the amount of $240.10001 million.

CEO, President & Director notifies of intention to sell stock

Nkarta: Possible Upside From H1 Update, If Positive

CEO, President & Director recently sold US$85k worth of stock

Price target increased by 7.7% to US$16.00

Here's Why We're Watching Nkarta's (NASDAQ:NKTX) Cash Burn Situation

Nkarta, Inc. Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition

Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

Price target decreased by 11% to US$17.38

We're Keeping An Eye On Nkarta's (NASDAQ:NKTX) Cash Burn Rate

New minor risk - Market cap size

Nkarta, Inc. Appoints Alyssa Levin as Chief Financial Officer

Nkarta, Inc. Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia

New minor risk - Share price stability

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Nkarta, Inc. to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

Insufficient new directors

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Nkarta, Inc. Promotes David R. Shook to Chief Medical Officer

Price target decreased to US$30.36

Nkarta, Inc. Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation

High number of new directors

Nkarta, Inc. to Report Q3, 2022 Results on Nov 09, 2022

CEO, President & Director notifies of intention to sell stock

Nkarta GAAP EPS of -$0.61

Chief Financial & Business Officer exercised options and sold US$71k worth of stock

Nkarta, Inc. Announces Executive Changes

Price target decreased to US$43.56

We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate

Nkarta: A Promising Natural Killer Cell Play

Price target decreased to US$44.11

Nkarta, Inc. Announces Executive Changes

High number of new directors

Nkarta Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs

Nkarta, Inc., Annual General Meeting, Jun 08, 2022

Nkarta, Inc. Appoints Angela M. Thedinga to its Board of Directors

Price target decreased to US$64.71

Nkarta, Inc. Presents NKX019 Trial in Progress Poster At the 2021 ASH Annual Meeting and Exposition

Insider notifies of intention to sell stock

CEO, President & Director notifies of intention to sell stock

Insider exercised options and sold US$118k worth of stock

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Chief Scientific Officer exercised options and sold US$62k worth of stock

Nkarta, Inc.(NasdaqGS:NKTX) dropped from Russell 2500 Growth Index

CEO, President & Director notifies of intention to sell stock

Insider notifies of intention to sell stock

Chief Financial & Business Officer notifies of intention to sell stock

Nkarta (NASDAQ:NKTX) Is In A Good Position To Deliver On Growth Plans

Chief Scientific Officer exercised options and sold US$62k worth of stock

Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies

Nkarta gets greenlight from the FDA for NKX019 cancer study

CEO, President & Director notifies of intention to sell stock

Chief Financial & Business Officer exercised options and sold US$246k worth of stock

マネジメント基準チェック /34